Ozempic Lawsuit Highlights Vision Loss Claims
PUBLISHED Oct 15, 2026, 11:17 AM ET
Read, Watch or Listen
In 2023, a Maryland resident began using Ozempic to manage diabetes, a drug also popular for weight loss. About four months later, he was diagnosed with non‑arteritic anterior ischemic optic neuropathy, an eye stroke that can cause sudden vision loss. On New Year’s Eve, 2024, he reported total blindness in one eye, and ten months later, the other eye was affected. He stopped the medication after the second loss and filed a lawsuit against Novo Nordisk, alleging the company failed to warn patients of the risk. The case joins hundreds of similar claims against GLP‑1 drugs, raising questions about safety disclosures and regulatory oversight. The lawsuit underscores the tension between therapeutic benefits and rare but severe side effects. It also highlights the need for clearer communication from manufacturers and healthcare providers. As more patients report similar incidents, the legal and medical communities face pressure to reassess risk‑
By Elena V. | JQJO News
Timeline of Events
- 2023 — Patient began Ozempic for diabetes management
- On October 1 2024 Second eye lost vision ten months after first incident.
- On March 24 2026 Lawsuit update cites growing number of GLP‑1 related claims.
News Intelligence
- Immediate US impact: U.S. readers following Business news get a clear update on: Ozempic Lawsuit Highlights Vision Loss Claims.
- Possible long-term US impact: Shapes near-term follow-up coverage and reader understanding of how this story may develop.
- Most affected groups: General news audiences, people directly named in the reporting, and readers tracking this beat.
- Reader priority: High for readers already following this storyline; moderate for a general U.S. audience.
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Right
No right-leaning sources found for this story.
Comments